Your browser doesn't support javascript.
loading
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium.
Rokx, C; Prins, H A B; Vandekerckhove, L; Fidler, S J; Frater, J; Bracchi, M; Søgaard, O S; Tolstrop, M; Rasmussen, T A; Salgado, M; Blanco, J; Martinez-Picado, J; Clotet, B; Tambussi, G; Groenendijk, A; Verbon, A; Boucher, C A B.
Afiliación
  • Rokx C; Erasmus MC University Medical Center, Netherlands.
  • Prins HAB; Erasmus MC University Medical Center, Netherlands.
  • Vandekerckhove L; Ghent University, Belgium.
  • Fidler SJ; Imperial College London, United Kingdom.
  • Frater J; University of Oxford, United Kingdom.
  • Bracchi M; Chelsea and Westminster Hospital, United Kingdom.
  • Søgaard OS; Aarhus University Hospital, Denmark.
  • Tolstrop M; Aarhus University Hospital, Denmark.
  • Rasmussen TA; Aarhus University Hospital, Denmark.
  • Salgado M; IrsiCaixa Barcelona, Spain.
  • Blanco J; IrsiCaixa Barcelona, Spain.
  • Martinez-Picado J; IrsiCaixa Barcelona, Spain.
  • Clotet B; IrsiCaixa Barcelona, Spain.
  • Tambussi G; San Raffaele Scientific Institute Milan, Italy.
  • Groenendijk A; Erasmus MC University Medical Center, Netherlands.
  • Verbon A; Erasmus MC University Medical Center, Netherlands.
  • Boucher CAB; Erasmus MC University Medical Center, Netherlands.
J Virus Erad ; 7(2): 100045, 2021 Jun.
Article en En | MEDLINE | ID: mdl-34141442
ABSTRACT
We felt the urgency to launch the EU2Cure Consortium to support research and find a cure for the human immunodeficiency virus (HIV) infection through intensified collaboration within Europe. This consortium is open to stakeholders on cure in Europe from academia and the community to connect. The aim of this consortium is to intensify the research collaboration amongst European HIV cure groups and the community and facilitate interactions with other academic and community cure consortia, private parties, and policy makers. Our main aim is to create a European research agenda, data sharing, and development of best practice for clinical and translational science to achieve breakthroughs with clinically feasible HIV cure strategies. This consortium should also enable setting up collaborative studies accessible to a broader group of people living with HIV. Besides reservoir studies, we have identified three overlapping scientific interests in the consortium that provide a starting point for further research within a European network developing "shock and kill" cure strategies, defining HIV cure biomarkers, and connecting cure cohorts. This strategy should aid stakeholders to sustain progress in HIV cure research regardless of coincidental global health or political crises.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: J Virus Erad Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: J Virus Erad Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos